Cite
HARVARD Citation
Tolaney, S. et al. (2023). Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Lancet oncology. 24 (3), pp. 273-285. [Online].